Nucleoside Reverse Transcriptase Inhibitors
DBCAT002755Pharmacologic class
A DrugBank category of 13 drugs. 9 of them are approved.
- Part of
- Antiviral Agents
What you can answer from here — as of July 15, 2019
Which targets do Nucleoside Reverse Transcriptase Inhibitors share, and which companies have late-stage candidates in this class?
Create a free account or log in to explore the full data card.
Create Account